**S3 Appendix. CONSORT 2010 checklist of information to include when reporting a cluster randomised trial (Campbell et al 2012)**

| Section/topic and item No | Standard checklist item | Extension for cluster designs | Page No\* |
| --- | --- | --- | --- |
| **Title and abstract** |
| 1a | Identification as a randomised trial in the title | Identification as a cluster randomised trial in the title | Title |
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)11 12 | See table 2 | Abstract |
| **Introduction** |
| Background and objectives: |  |  |  |
|  2a | Scientific background and explanation of rationale | Rationale for using a cluster design | Methods (design) p.6, and in discussion |
|  2b | Specific objectives or hypotheses | Whether objectives pertain to the cluster level, the individual participant level, or both | Individual level p.5 |
| **Methods** |
| Trial design: |  |  |  |
|  3a | Description of trial design (such as parallel, factorial) including allocation ratio | Definition of cluster and description of how the design features apply to the clusters | Care home p.6, under Design |
|  3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons |  | Na |
| Participants: |  |  |  |
|  4a | Eligibility criteria for participants | Eligibility criteria for clusters | See inclusion criteria under participants p.7 |
|  4b | Settings and locations where the data were collected |  | SW Wales p.6 |
| Interventions: |  |  |  |
|  5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | Whether interventions pertain to the cluster level, the individual participant level, or both | Intervention is appended - Appendix S1 |
| Outcomes: |  |  |  |
|  6a | Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed | Whether outcome measures pertain to the cluster level, the individual participant level, or both | Individual, see Data collection p.9&protocol registration |
|  6b | Any changes to trial outcomes after the trial commenced, with reasons |  | None |
| Sample size: |  |  |  |
|  7a | How sample size was determined | Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or *k*), and an indication of its uncertainty | Methods, sample size p.8In our feasibility before and after study24 a mean of 3.0 [SD 5.4] more problems were addressed following administration of the Profile, and the intra-cluster correlation coefficient (ICC) was close to zero. To investigate whether this improvement would be replicated in a larger sample would require a total sample of 28, with 80% power, 5% alpha, two sided54. With 10 participants in each cluster, an ICC of 0.05, and a design effect of 1.45, we calculated that 41 participants were needed55. We planned to recruit 50 participants from 5 sites, and anticipated 10% loss to follow up over 6 months.  |
|  7b | When applicable, explanation of any interim analyses and stopping guidelines |  | None |
| **Randomisation** |
| Sequence generation: |  |  |  |
|  8a | Method used to generate the random allocation sequence |  | This is contained in: Russell, D., Hoare, Z.S.J., Whitaker, Rh., Whitaker, C.J., & Russell, I.T. (2011) Generalized method for adaptive randomization in clinical trials. *Statistics in Medicine*. **30**(9), 922-934. |
|  8b | Type of randomisation; details of any restriction (such as blocking and block size) | Details of stratification or matching if used | None |
| Allocation concealment mechanism: |  |  |  |
| 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level, or both | Randomisation p.8. Allocation concealment was impossible, limitations, blinding p30. |
| Implementation: |  |  |  |
|  10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | Replaced by 10a, 10b, and 10c | Swansea University Clinical Trials Unit (CTU) p.8 |
|  10a |  | Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions | CTU p.8, MG, randomisation process |
|  10b |  | Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete enumeration, random sampling) | Resident in care home, see inclusion criteria p.7 |
|  10c |  | From whom consent was sought (representatives of the cluster, or individual cluster members, or both) and whether consent was sought before or after randomisation | Individual consent was sought after randomisation, Ethics p.13. However, all participants received the intervention. Randomisation only affected timing. Design p.6 |
| Blinding: |  |  |  |
|  11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how |  | None |
|  11b | If relevant, description of the similarity of interventions |  | Na |
| Statistical methods: |  |  |  |
|  12a | Statistical methods used to compare groups for primary and secondary outcomes | How clustering was taken into account | Controlled in analysis p.10 |
|  12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses |  | No subgroups,Adjustments listed p.10, table 6 |
| **Results** |
| Participant flow (a diagram is strongly recommended): |  |  | Fig 2 |
|  13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome | Table 1 |
|  13b | For each group, losses and exclusions after randomisation, together with reasons | For each group, losses and exclusions for both clusters and individual cluster members | Table 1, figure 2 |
| Recruitment: |  |  |  |
|  14a | Dates defining the periods of recruitment and follow-up |  | May- October 2013 |
|  14b | Why the trial ended or was stopped |  | Fully completed |
| Baseline data: |  |  |  |
|  15 | A table showing baseline demographic and clinical characteristics for each group | Baseline characteristics for the individual and cluster levels as applicable for each group | Table 1 |
| Numbers analysed: |  |  |  |
|  16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | For each group, number of clusters included in each analysis | Table 1. statement p.15 |
| Outcomes and estimation: |  |  |  |
|  17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or *k*) for each primary outcome | Tables 2-8 ICCs are listed in Table 6 |
|  17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended |  | Tables 2-8 |
| Ancillary analyses: |  |  |  |
|  18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory |  | No subgroups, adjusted analyses table 6 |
| Harms: |  |  |  |
|  19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms106) |  | Outcome 4 p.27-28 |
| **Discussion** |
| Limitations: |  |  |  |
|  20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses |  | Strengths and limitations p28-31 |
| Generalisability: |  |  |  |
|  21 | Generalisability (external validity, applicability) of the trial findings | Generalisability to clusters and/or individual participants (as relevant) | Strengths and limitations |
| Interpretation: |  |  |  |
|  22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence |  | Discussion p.31-35 |
| **Other information** |
| Registration: |  |  |  |
|  23 | Registration number and name of trial registry |  | Trial registration: ISRCTN48133332 10.1186/ISRCTN48133332  |
| Protocol: |  |  |  |
|  24 | Where the full trial protocol can be accessed, if available |  | From authors |
| Funding: |  |  |  |
|  25 | Sources of funding and other support (such as supply of drugs), role of funders |  | Wales School for Primary Care Research, National Institute for Social Care and Health Research , Cardiff. Funders played no role in the study. |

**\*Page numbers optional depending on journal requirements.**